BCAL Diagnostics announce that it has completed the processing of 301 samples as part of its Cohort 4 testing, with the positive results having the potential to accelerate development of BCAL's test. New scientific data strongly reinforces previous results; Value of 18 candidate lipid biomarker panel in diagnosing breast cancer confirmed; Potential for acceleration of commercial use of test; Patient recruitment underway for new clinical study ? successful recruitment of 150 patients to date; Clinical study sites continue to expand. The clinical data and results of the combined Cohort 4 and Cohort 3 testing are in alignment with previously reported specificity and accuracy of the test in early-stage detection of breast cancer. Reproducing these results to such a high standard reinforces the continued scientific development and advancement of the science by BCAL's team. The results are based on the 18 candidate lipid marker panel, as previously identified, with pathways to accelerate development of the test showing significant potential. The data analysis is continuing as BCAL seeks to further refine its algorithm and biomarker development. BCAL has also appointed an international consulting group, with a wealth of relevant international expertise in the development of in vitro diagnostic products, to assist with algorithm optimisation. With the scientific progress continuing on course, BCAL is actively recruiting patients for the Stage I clinical trial of the test, with 150 already secured. Patients are currently being recruited at clinical study sites including Sydney Breast Clinic and Chris O'Brien Lifehouse, with BreastScreen NSW to commence upon reopening post lockdown measures.